Absolute lymphocyte count is an independent predictor of survival in patients with metastatic renal cell carcinoma treated with nivolumab.
Kousuke UedaShigetaka SuekaneHirofumi KuroseNaoyuki OgasawaraTasuku HiroshigeKatsuaki ChikuiKeiichiro UemuraMakoto NakiriKiyoaki NishiharaMitsunori MatsuoTsukasa IgawaPublished in: Japanese journal of clinical oncology (2021)
Our study indicates that peripheral absolute lymphocyte count, before nivolumab initiation, is a predictor of poor response in metastatic renal cell carcinoma. Additionally, increased absolute lymphocyte count, 1 month post-nivolumab initiation, can be a predictor of the effects of nivolumab.